الفهرس | Only 14 pages are availabe for public view |
Abstract Intravitreal injection (IV) of anti-vascular endothelial growth factor (anti-VEGF) agents are increasingly used for the treatment of retinal vascular diseases. Bevacizumab (AvastinTM) and ranibizumab (LucentisTM) are the most frequently used anti-VEGF agents in ophthalmology and which are both antibodies to VEGF. Despite the fact that the safety of these agents is generally approved by many physicians, some serious systemic and ocular complications can be seen after the injections. This descriptive prospective study was carried out to assess the effect of intravitreal injection of ranibizumab on central corneal thickness and intraocular pressure within one week after injection in 38 eyes by ultrasound pachymeter and goldman applanation tonometer of 38 selected patients who attended the outpatient clinic of Ophthalmology department of Menoufia University for intravitreal injection of ranibizumab because of retinal venous occlusion (RVO), diabetic retinopathy, macular edema and choroidal neovascularization (CNV). All Including patients are adult patients from 18 to 70 years of age both gender with crystalline clear cornea devoided from any corneal dystrophy and degenerations, corneal thickness more than 400 mm. Excluding patients with glaucoma, patients less than 18 years old, local eye disease and previous surgery, preoperative corneal thickness less than 400 mm any type of corneal pathology as corneal degeneration and, corneal dystrophy. Summary 57 All patients underwent a complete baseline ophthalmological examination, full medical and ophthalmic history, clinical examination including BCVA, slit-lamp examination, fundus examination by slit-lamp bio microscopy using 90D lens. IOP and CCT examination performed before, same day, first day,and one week after intravetreal injection. Our study included 38 patients (11 males and 27 females) with retinal vascular diseases and their ages ranged from 31 to 71 years with a mean age of 59.87 ± 9.88 years. More than half patients (55.3%) had their left eye affected. Out of 38 patients, 57.9% were diabetic and 28.9% were hypertensive. The most common indication for ranibizumab injection was proliferative diabetic retinopathy in 34.2% of the studied patients followed by CNV in 26.3% then BRVO and CME, each elicited by 15.8% of patients. Before ranibizumab injection, the mean IOP was 15.84 ± 2.75 mmHg which was increased the same day after injection to be 24.18 ± 4.22 mmHg, started decreasing after 1 day and one week with a mean of 16.34 ± 2.36 and 15.18 ± 2.32 mmHg respectively. Before ranibizumab injection, the mean CT was 525.03 ± 43.99 μm which was increased the same day after injection to be 555.08 ± 47.39 μm, started decreasing after 1 day and one week with a mean of 543.55 ± 44.83 and 525.32 ± 42.59 μm respectively. |